Abstract:Background A novel anti-rheumatic drug, T-614, has been shown to have an anti-inflammatory effect and to improve abnormal immunological findings in rheumatoid arthritis (RA). To assess the safety and efficacy of T-614 versus placebo in patients with active RA we conducted a 24-week clinical study in 280 Chinese patients.Methods In a multicenter, randomized, double blind, placebo controlled study, 280 patients were randomly assigned to receive placebo (n=95) or T-614 at 50 mg (n=93) or 25 mg (n=92) daily. Active disease was defined by 4 of the following 5 criteria: 2 5 tender joints, 2:3 swollen joints, morning stiffness lasting for 60 minutes, and Westergren erythrocyte sedimentation rate (ESR) >= 28 mm/h, the assessment of pain at the rest by patient as moderate or severe. Clinical and laboratory parameters were analyzed at baseline, 2, 4, 6, 12, 18 and 24 weeks. The primary efficacy variable at week 24 was the American College of Rheumatology (ACR) response rate using the intent-to-treat population.Results The ACR response rate was significantly higher in the T-614 treatment group compared with the placebo group within 8 weeks after the initiation of treatment. After 24 weeks, the 25 mg/d and 50 mg/d dosage groups and the placebo group showed 39.13%, 61.29% and 24.21% in ACR20 and 23.91%, 31.18% and 7.37% in ACR50, respectively. A time-response in ACR response was observed, with clear superiority for the 25 mg/d and 50 mg/d dosage groups compared to placebo (P<0.0001), and the 50 mg/d dose compared to the 25 mg/d dose (P<0.05) when using the ACR response analyses after 24 weeks. ESR and c-reactive protein (CRP) were significantly different in the treatment groups after 24 weeks. The incidence of adverse events (AEs) was not significantly higher with T-614 than with placebo, but upper abdominal discomfort, leucopenia, elevated serum alanine aminotransferase (sALT), skin rash and/or pruritus were more common in the 50 mg and 25 mg dosage groups.Conclusion T-614, a new slow-acting drug, is effective in treatment of rheumatoid arthritis and is well tolerated.

T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis

Inhibitory Effect of a Novel Antirheumatic Drug T-614 on the IL-6-Induced RANKL/OPG, IL-17, and MMP-3 Expression in Synovial Fibroblasts from Rheumatoid Arthritis Patients

L161982 alleviates collagen-induced arthritis in mice by increasing Treg cells and down-regulating Interleukin-17 and monocyte-chemoattractant protein-1 levels

T-614 Alters the Production of Matrix Metalloproteinases (MMP-1 Andmmp-3) and Inhibits the Migratory Expansion of Rheumatoid Synovial Fibroblasts, in Vitro.

Comparable Therapeutic Potential of Umbilical Cord Mesenchymal Stem Cells in Collagen-Induced Arthritis to TNF Inhibitor or Anti-Cd20 Treatment.

Co-Expression of Il-18 Binding Protein and Il-4 Regulates Th1/Th2 Cytokine Response in Murine Collagen-Induced Arthritis

T-614 Promotes Osteoblastic Cell Differentiation by Increasing Dlx5 Expression and Regulating the Activation of P38 and NF-κB

Therapeutic effects of a novel tylophorine analog, NK-007, on collagen-induced arthritis through suppressing tumor necrosis factor α production and Th17 cell differentiation.

Safety and Efficacy of T-614 in the Treatment of Patients with Active Rheumatoid Arthritis: A Double Blind, Randomized, Placebo-Controlled and Multicenter Trial

Therapeutic Effects Of Taci-Ig On Rats With Adjuvant-Induced Arthritis Via Attenuating Inflammatory Responses

Inhibitory Effect of the Antimalarial Agent Artesunate on Collagen-Induced Arthritis in Rats Through Nuclear Factor Kappa B and Mitogen-Activated Protein Kinase Signaling Pathway

Progress of experimental and therapeutic research for effects of iguratimod(T-614) on rheumatoid arthritis

Tectoridin exhibits anti-rheumatoid arthritis activity through the inhibition of the inflammatory response and the MAPK pathway in vivo and in vitro

Therapeutic Effect of Cryptotanshinone on Collagen-Induced Arthritis in Rats Via Inhibiting Nuclear Factor Kappa B Signaling Pathway

Immune regulatory and anti‐resorptive activities of tanshinone IIA sulfonate attenuates rheumatoid arthritis in mice

Therapeutic effects of lactosyl derivative Gu-4 in a collagen-induced arthritis rat model

The experimental study on the effect of rhTNFR:Fc and methtotrexate-rhTNFR:Fc on joint destruction of collagen-induced arthritis rat

Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice

Multicenter, Randomized, Double-Blind, Controlled Trial of Treatment of Active Rheumatoid Arthritis with T-614 Compared with Methotrexate.

Adenovirus-Mediated Small Interfering RNA Targeting TAK1 Ameliorates Joint Inflammation with Collagen-Induced Arthritis in Mice

Therapeutic Effect of Matrine on Collagen-Induced Arthritis Rats and Its Regulatory Effect on RANKL and OPG Expression